Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 2
2018 3
2019 7
2020 7
2021 12
2022 13
2023 11
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V, Rosenberger LH, Hwang ES, Ingham A, Papassotiropoulos B, Nguyen-Sträuli BD, Kurzeder C, Aybar DD, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Karanlik H, Dedes KJ, Romics L, Banys-Paluchowski M, Muslumanoglu M, Perez MDRC, Díaz MC, Heidinger M, Fehr MK, Reinisch M, Tukenmez M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Paulinelli RR, Zarhi SS, Kuemmel S, Bruzas S, di Lascio S, Parissenti TK, Hoskin TL, Güth U, Ovalle V, Tausch C, Kuerer HM, Caudle AS, Boileau JF, Boughey JC, Kühn T, Morrow M, Weber WP. Montagna G, et al. Among authors: riedel f. JAMA Oncol. 2024 Jun 1;10(6):793-798. doi: 10.1001/jamaoncol.2024.0578. JAMA Oncol. 2024. PMID: 38662396
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.
Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV, Benson J, Bese N, Boughey JC, Boyle MK, Diego EJ, Eden C, Eller R, Goldschmidt M, Hlavin C, Heidinger M, Jelinska J, Karadeniz Cakmak G, Kesmodel SB, King TA, Kuerer HM, Loesch J, Milardi F, Murawa D, Moo TA, Menes TS, Passeri D, Pastoriza JM, Perhavec A, Pislar N, Polidorio N, Rami A, Ryu JM, Schulz A, Sevilimedu V, Ugurlu MU, Uras C, van Hemert A, Wong SM, Yoo TR, Zhang JQ, Karanlik H, Cabioğlu N, Peeters MV, Morrow M, Weber WP; ICARO Study Group. Montagna G, et al. J Clin Oncol. 2025 Mar;43(7):810-820. doi: 10.1200/JCO.24.01052. Epub 2024 Nov 7. J Clin Oncol. 2025. PMID: 39509672 Free PMC article.
Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
von Au A, Shencoru S, Uhlmann L, Mayer L, Michel L, Wallwiener M, Hennigs A, Deutsch T, Riedel F, Heil J, Golatta M, Schneeweiss A, Schütz F, Domschke C. von Au A, et al. Among authors: riedel f. Arch Gynecol Obstet. 2023 Apr;307(4):1105-1113. doi: 10.1007/s00404-022-06726-7. Epub 2022 Aug 18. Arch Gynecol Obstet. 2023. PMID: 35980458 Free PMC article.
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.
Fischer C, Deutsch TM, Feisst M, Rippinger N, Riedel F, Hartkopf AD, Brucker SY, Domschke C, Fremd C, Michel L, Burwinkel B, Schneeweiss A, Turchinovich A, Wallwiener M. Fischer C, et al. Among authors: riedel f. Arch Gynecol Obstet. 2022 Sep;306(3):875-885. doi: 10.1007/s00404-022-06442-2. Epub 2022 Mar 2. Arch Gynecol Obstet. 2022. PMID: 35237856 Free PMC article.
Time trends of neoadjuvant chemotherapy for early breast cancer.
Riedel F, Hoffmann AS, Moderow M, Heublein S, Deutsch TM, Golatta M, Wallwiener M, Schneeweiss A, Heil J, Hennigs A. Riedel F, et al. Int J Cancer. 2020 Dec 1;147(11):3049-3058. doi: 10.1002/ijc.33122. Epub 2020 Jun 13. Int J Cancer. 2020. PMID: 32468577
57 results